128 related articles for article (PubMed ID: 30979616)
1. PD-1 Tumor Suppressor Signaling in T Cell Lymphomas.
Wartewig T; Ruland J
Trends Immunol; 2019 May; 40(5):403-414. PubMed ID: 30979616
[TBL] [Abstract][Full Text] [Related]
2. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.
Wartewig T; Kurgyis Z; Keppler S; Pechloff K; Hameister E; Öllinger R; Maresch R; Buch T; Steiger K; Winter C; Rad R; Ruland J
Nature; 2017 Dec; 552(7683):121-125. PubMed ID: 29143824
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.
Zhou K; Guo S; Tong S; Sun Q; Li F; Zhang X; Qiao Y; Liang G
Stem Cells Dev; 2018 Sep; 27(17):1191-1202. PubMed ID: 29978730
[TBL] [Abstract][Full Text] [Related]
4. Mathematical modeling identifies Lck as a potential mediator for PD-1 induced inhibition of early TCR signaling.
Arulraj T; Barik D
PLoS One; 2018; 13(10):e0206232. PubMed ID: 30356330
[TBL] [Abstract][Full Text] [Related]
5. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
6. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
7. Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment.
Gao Y; Hu S; Li R; Jin S; Liu F; Liu X; Li Y; Yan Y; Liu W; Gong J; Yang S; Tu P; Shen L; Bai F; Wang Y
JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36649072
[TBL] [Abstract][Full Text] [Related]
8. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
9. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
[TBL] [Abstract][Full Text] [Related]
10. PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma.
Wartewig T; Daniels J; Schulz M; Hameister E; Joshi A; Park J; Morrish E; Venkatasubramani AV; Cernilogar FM; van Heijster FHA; Hundshammer C; Schneider H; Konstantinidis F; Gabler JV; Klement C; Kurniawan H; Law C; Lee Y; Choi S; Guitart J; Forne I; Giustinani J; Müschen M; Jain S; Weinstock DM; Rad R; Ortonne N; Schilling F; Schotta G; Imhof A; Brenner D; Choi J; Ruland J
Nat Cancer; 2023 Oct; 4(10):1508-1525. PubMed ID: 37723306
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
[TBL] [Abstract][Full Text] [Related]
13. Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.
Kobold S; Grassmann S; Chaloupka M; Lampert C; Wenk S; Kraus F; Rapp M; Düwell P; Zeng Y; Schmollinger JC; Schnurr M; Endres S; Rothenfußer S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26105028
[TBL] [Abstract][Full Text] [Related]
14. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
15. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
16. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Schlenker R; Olguín-Contreras LF; Leisegang M; Schnappinger J; Disovic A; Rühland S; Nelson PJ; Leonhardt H; Harz H; Wilde S; Schendel DJ; Uckert W; Willimsky G; Noessner E
Cancer Res; 2017 Jul; 77(13):3577-3590. PubMed ID: 28533272
[TBL] [Abstract][Full Text] [Related]
17. [Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].
Hamanishi J; Konishi I
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1071-6. PubMed ID: 25248890
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4
Celada LJ; Rotsinger JE; Young A; Shaginurova G; Shelton D; Hawkins C; Drake WP
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):74-82. PubMed ID: 27564547
[TBL] [Abstract][Full Text] [Related]
19. PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.
Karyampudi L; Lamichhane P; Krempski J; Kalli KR; Behrens MD; Vargas DM; Hartmann LC; Janco JM; Dong H; Hedin KE; Dietz AB; Goode EL; Knutson KL
Cancer Res; 2016 Jan; 76(2):239-50. PubMed ID: 26567141
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
